176 related articles for article (PubMed ID: 19165610)
1. BRMS1 contributes to the negative regulation of uPA gene expression through recruitment of HDAC1 to the NF-kappaB binding site of the uPA promoter.
Cicek M; Fukuyama R; Cicek MS; Sizemore S; Welch DR; Sizemore N; Casey G
Clin Exp Metastasis; 2009; 26(3):229-37. PubMed ID: 19165610
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis.
Liu Y; Smith PW; Jones DR
Mol Cell Biol; 2006 Dec; 26(23):8683-96. PubMed ID: 17000776
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity.
Cicek M; Fukuyama R; Welch DR; Sizemore N; Casey G
Cancer Res; 2005 May; 65(9):3586-95. PubMed ID: 15867352
[TBL] [Abstract][Full Text] [Related]
4. PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-κB- and HDAC1-mediated expression and activation of uPA.
Zou Z; Zeng F; Xu W; Wang C; Ke Z; Wang QJ; Deng F
J Cell Sci; 2012 Oct; 125(Pt 20):4800-11. PubMed ID: 22797919
[TBL] [Abstract][Full Text] [Related]
5. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression.
Ashburner BP; Westerheide SD; Baldwin AS
Mol Cell Biol; 2001 Oct; 21(20):7065-77. PubMed ID: 11564889
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation.
Samant RS; Clark DW; Fillmore RA; Cicek M; Metge BJ; Chandramouli KH; Chambers AF; Casey G; Welch DR; Shevde LA
Mol Cancer; 2007 Jan; 6():6. PubMed ID: 17227585
[TBL] [Abstract][Full Text] [Related]
7. MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells.
Mori Y; Akita K; Tanida S; Ishida A; Toda M; Inoue M; Yashiro M; Sawada T; Hirakawa K; Nakada H
J Biol Chem; 2014 Dec; 289(51):35193-204. PubMed ID: 25371209
[TBL] [Abstract][Full Text] [Related]
8. BRMS1 inhibits expression of NF-kappaB subunit p65, uPA and OPN in ovarian cancer cells.
Sheng XJ; Zhou DM; Liu Q; Lou SY; Song QY; Zhou YQ
Eur J Gynaecol Oncol; 2014; 35(3):236-42. PubMed ID: 24984534
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1.
Liu Y; Mayo MW; Nagji AS; Smith PW; Ramsey CS; Li D; Jones DR
Oncogene; 2012 Mar; 31(9):1143-54. PubMed ID: 21765477
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.
Pulukuri SM; Gorantla B; Rao JS
J Biol Chem; 2007 Dec; 282(49):35594-603. PubMed ID: 17923479
[TBL] [Abstract][Full Text] [Related]
11. Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells.
Batra S; Sahu RP; Kandala PK; Srivastava SK
Mol Cancer Ther; 2010 Jun; 9(6):1596-608. PubMed ID: 20484017
[TBL] [Abstract][Full Text] [Related]
12. Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2.
Bhat KP; Pelloski CE; Zhang Y; Kim SH; deLaCruz C; Rehli M; Aldape KD
FEBS Lett; 2008 Sep; 582(21-22):3193-200. PubMed ID: 18708058
[TBL] [Abstract][Full Text] [Related]
13. Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
Li H; Ye X; Mahanivong C; Bian D; Chun J; Huang S
J Biol Chem; 2005 Mar; 280(11):10564-71. PubMed ID: 15653692
[TBL] [Abstract][Full Text] [Related]
14. Tumor suppressor SMAR1 represses IkappaBalpha expression and inhibits p65 transactivation through matrix attachment regions.
Singh K; Sinha S; Malonia SK; Bist P; Tergaonkar V; Chattopadhyay S
J Biol Chem; 2009 Jan; 284(2):1267-78. PubMed ID: 18981184
[TBL] [Abstract][Full Text] [Related]
15. Exchange of a nuclear corepressor between NF-kappaB and CREB mediates inhibition of phosphoenolpyruvate carboxykinase transcription by NF-kappaB.
Yan JH; Gao ZG; Ye JP; Weng JP
Chin Med J (Engl); 2010 Jan; 123(2):221-6. PubMed ID: 20137375
[TBL] [Abstract][Full Text] [Related]
16. Dimethylcelecoxib induces an inhibitory complex consisting of HDAC1/NF-κB(p65)RelA leading to transcriptional downregulation of mPGES-1 and EGR1.
Deckmann K; Rörsch F; Geisslinger G; Grösch S
Cell Signal; 2012 Feb; 24(2):460-467. PubMed ID: 21983014
[TBL] [Abstract][Full Text] [Related]
17. Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells.
Reuning U; Guerrini L; Nishiguchi T; Page S; Seibold H; Magdolen V; Graeff H; Schmitt M
Eur J Biochem; 1999 Jan; 259(1-2):143-8. PubMed ID: 9914486
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB.
Sliva D; English D; Lyons D; Lloyd FP
Biochem Biophys Res Commun; 2002 Jan; 290(1):552-7. PubMed ID: 11779207
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
Wang W; Abbruzzese JL; Evans DB; Chiao PJ
Oncogene; 1999 Aug; 18(32):4554-63. PubMed ID: 10467400
[TBL] [Abstract][Full Text] [Related]
20. RNA-destabilizing factor tristetraprolin negatively regulates NF-kappaB signaling.
Liang J; Lei T; Song Y; Yanes N; Qi Y; Fu M
J Biol Chem; 2009 Oct; 284(43):29383-90. PubMed ID: 19738286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
